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Abstract
Background: Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a natural inhibitor of the matrix metalloproteinases 
(MMPs) which are proteolytic enzymes involved in degradation of extracellular matrix thereby favoring tumour cell 
invasion and metastasis. TIMP-1 activity in tumour tissue may therefore play an essential role in the progression of a 
malignant tumour.
The primary aim of the present study was to evaluate TIMP-1 protein immunoreactivity in tissue from primary ovarian
cancer patients and associate these findings with the course of the disease including response to treatment in the
individual patient.
Methods: TIMP-1 was assessed by immunohistochemistry (in tissue micro arrays) in a total of 163 ovarian cancer 
specimens obtained from primary debulking surgery during 1991-1994 as part of a randomized clinical protocol.
Results: Positive TIMP-1 immunoreactivity was found in 12.3% of the tumours. The median survival time for the 143 
patients with TIMP-1 negative tumours was 23.7 months [19.0-29.4] 95% CI, while the median survival time for the 20 
patients with TIMP-1 positive tumours was 15.9 months [12.3-27.4] 95% CI. Although a difference of 7.8 months in 
median overall survival in favor of the TIMP-1 tumour negative patients was found, this difference did not reach 
statistical significance (p = 0.28, Kaplan-Meier, log-rank test). Moreover, TIMP-1 immunoreactivity was not associated 
with CA125 response (p = 0.53) or response at second look surgery (p = 0.72).
Conclusion: TIMP-1 immunoreactivity in tumour tissue from patients with primary epithelial ovarian cancer did not 
correlate with patient survival or response to combination platinum/cyclophosphamide therapy.
Background
Epithelial ovarian cancer is the leading cause of gyneco-
logic-related cancer deaths. The cornerstone of treatment
is debulking surgery and platinum-based chemotherapy
with succeeding complete clinical response for the major-
ity of the patients. Unfortunately, a high percentage of the
patients experience relapse of their disease, and treat-
ment for recurrent disease has not achieved convincing
success rates. Therefore, scientific efforts have focused on
improving current treatment. In this context, the use of
biological or molecular markers for predicting patient
outcome including selection of the most effective treat-
ment for the individual patient has attracted a lot of inter-
est. The most widely used tumour marker in ovarian
cancer is CA125. This biomarker is used to evaluate diag-
nosis, treatment efficacy and to monitor disease status
although there are several limitations in the interpreta-
tion of CA125 such as inadequate sensitivity and specific-
ity. In recent years, a new biological marker of potential
usefulness for early detection, prognosis, prediction and
monitoring of a variety of tumour types has been sug-
gested [1]. This marker, tissue inhibitor of matrix metal-
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Page 2 of 10loproteinase-1 (TIMP-1) is one among four members of
the TIMP family. These proteins are natural inhibitors of
the matrix metalloproteinases (MMPs) and play a key
role in maintaining homeostasis of the extracellular
matrix by controlling the proteolytic activity of the
MMPs. In addition to its role in regulating MMPs, TIMP-
1 has also been shown to stimulate cell proliferation,
exhibit anti-apoptotic effects and to influence angiogene-
sis [1-6].
TIMP-1 immunohistochemical studies have shown
increased TIMP-1 immunoreactivity in gastric, breast
and renal carcinomas [7-9]. Moreover, several studies
have found a correlation between TIMP-1 protein levels
in blood or tumour tissue obtained from various cancer
types (breast, esophageal, gastric, renal, colorectal and
non-small cell lung carcinoma) and prognosis [7,8,10-15].
More recently, TIMP-1 levels have been associated with
response to therapy of breast [9,16] and colorectal cancer
[10]. Over-expression of TIMP-1 has also been reported
in ovarian cancer patients compared to patients with bor-
derline tumours, benign ovarian tumours or with normal
ovaries. The majority of these ovarian cancer studies have
investigated serum [17,18] or plasma [19] TIMP-1 levels
while only a few have investigated tissue TIMP-1 concen-
tration by ELISA technique [20], tissue TIMP-1 by in situ
mRNA hybridization and/or immunohistochemistry [21]
or TIMP activity by reverse zymography [22] and all
found increased TIMP-1 levels/expression in ovarian
cancer specimens. The assessment of serum concentra-
tions of TIMP-1 (and some metalloproteinases) appeared
to be useful in differentiating between malignant, border-
line and benign ovarian tumours [17,18] although some
overlaps between the groups were apparent. Further-
more, the studies were under-powered for diagnostic
purposes and no sensitivity or specificity was reported.
Only very limited published data exist on the prognos-
tic value of TIMP1 in ovarian cancer. One study including
40 patients with ovarian cancer found that increasing
preoperative plasma levels of TIMP-1 were associated
with poor survival [19]. A second study found that high
preoperative serum concentrations of TIMP-1 from 59
ovarian cancer patients were correlated with decreased
recurrence-free survival and overall survival in univariate
analysis [18]. However, no prior studies have investigated
the association between TIMP-1 immunoreactivity and
patient prognosis in epithelial ovarian cancer patients.
The primary aim of the present study was therefore to
evaluate whether TIMP-1 immunoreactivity in tissue
from primary ovarian cancer patients was associated with
overall survival of the patients. Moreover, it was tested
whether TIMP-1 immunoreactivity was associated with
treatment efficacy as evaluated by CA125 response and
response at second look surgery following treatment with
carboplatin and cyclophosphamide.
Methods
Study Population
From 1991 to 1994, 222 patients were prospectively
enrolled in the DACOVA (Danish Ovarian Cancer Study
Group) 9101 protocol [23]. In this study patients were
randomized to receive combination chemotherapy with
carboplatin and cyclophosphamide (500 mg/m2) with
carboplatin at a dose of AUC4 in one treatment arm or at
a dose of AUC8 in the other treatment arm. Neither pre-
liminary nor long-term results [24] showed any effect of
the higher carboplatin dose. Patients with stage II-IV and
with confirmed epithelial ovarian cancer were included
and collected data were entered into case report forms.
The protocol was approved by The Danish Biomedical
Research Ethics Committee and all patients were
required to provide written informed consent prior to
inclusion.
All patients were included into the protocol during
1991-1994. At that time the RECIST criteria did not exist
and therefore, the international recognized GCIG CA-
125 response criteria and not RECIST criteria were used
for response evaluation. Moreover, in ovarian cancer,
there are often no reliably measurable target lesions due
to predominantly diffuse peritoneal disease. Hence,
serum CA-125 levels are extensively used to assess
response and define progression in ovarian cancer and
often mirror the RECIST/WHO criteria [25].
CA125 serum levels were analyzed by routine methods
at the Clinical Chemistry Departments of the treating
hospitals. Full CA125 data were available on 106 of the
patients. The study was carried out in compliance with
the Helsinki Declaration and the Danish Biomedical
Research Ethics Committee approved the study accord-
ing to Danish law.
Preparation of tissue microarrays
Formalin-fixed, paraffin-embedded tissue blocks from
the primary tumour debulking, prior to first line chemo-
therapy, were retrieved from the Regional Departments
of Pathology. All cases underwent central pathology
review and were classified according to the WHO histo-
logical classification of ovarian tumours and graded
according to Silverberg [26]. Adequate specimens from
163 patients were selected for analysis. Patients not
included in the present study were a result of missing
blocks, lack of patient data, wrong pathology numbers or
lack of residual tumour tissue in the collected blocks. Fur-
thermore, at the central pathology review nine patients
were considered as not having primary ovarian cancer
but instead six cases with metastatic disease from
another primary tumour and three cases with borderline
ovarian tumours.
Tissue microarray (TMA) using Advanced Tissue
Arrayer ATA-100 (Chemicon, AH Diagnostics, Aarhus,
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were retrieved from areas of the original donor paraffin
block selected by a pathologist and arrayed into a newly
constructed recipient block. Tissue cores were 1 mm in
diameter (Fig 1). For each tumour 2 or 3 core samples of
tumour tissue were acquired from the donor block. The
TMA block also contained samples of normal tonsillar
and appendix tissue (placed in specific corners of the
TMA block to ensure correct orientation when examin-
ing the slides), which served as internal negative control.
A slide with breast cancer tissue served as internal posi-
tive controls.
For 20 patients whole-tissue sections were also evalu-
ated for TIMP-1 staining to investigate possible heteroge-
neity in the TIMP-1 immunoreactivity and to investigate
the correlation to the staining observed in the corre-
sponding TMA's.
TIMP-1 immunohistochemical staining
Freshly cut TMA and whole-slide paraffin sections were
stained with the monoclonal antibody VT-7, raised
against recombinant human TIMP-1 [27]. The antibody
is of the IgG1 subtype and was used in the concentration
0.25 μg/ml.
As a negative control, the irrelevant IgG1 monoclonal
antibody raised against trinitrophenyl hapten (TNP) was
used. For each immunohistochemical (IHC) run, a posi-
tive control case known to contain TIMP-1 was included.
Reagents used for IHC were obtained from Dako (Dako
Denmark A/S, Glostrup, Denmark) and used according
to the manufacturer's instructions. All staining proce-
dures were performed manually.
The paraffin sections (3 μm) were de-waxed in xylene
and rehydrated through a graded series of ethanol. Anti-
gen retrieval was carried out by boiling the sections for 10
min. in a conventional microwave oven in 10 mM citrate
buffer pH 6.0, followed by 30 min in the hot buffer at
room temperature. To block endogenous peroxidase
activity the sections were treated with 1% hydrogen per-
oxide for 10 min. Sections were incubated with primary
antibody overnight at 4°C.
Bound primary antibody was detected with Advance
HRP (Code No. K4068, Dako Denmark A/S, Glostrup,
Denmark), and the reactions were visualized by incubat-
ing the sections with diaminobenzidine tetrahydrochlo-
ride (DAB+) for 5 min. Between incubations the sections
were washed with TBS containing 0.5% Triton X-100.
Finally, the sections were counterstained with Mayer's
haematoxylin.
Evaluation of TIMP-1 immunohistochemical staining
The study pathologists (MW and RKC) independently
scored all the samples which were blinded for clinical
data. All the cores represented in the TMA's from a
tumour were scored. The vast majority of the cases had
identical scoring percentage and intensity of the different
cores and in the very few cases that deviated an average
was calculated and reported.
The percentage of TIMP-1 positive stained tumour
cells was rated as 0 = no cells stained positive, 1 =
between >0% and 10% positive, 2 = between >10% and
25%, 3 = between >25% and 50% and 4 = >50% positive
cells. Intensity score was made on the basis of the average
intensity of staining: 0 = absent, 1 = weak, 2 = moderate
and 3 = strong.
The tumour was scored as positive when >25% of the
total number of tumour cells stained with a moderate or
strong intensity.
Statistical analyses
The correlation between TIMP-1 expression and clinico-
pathological parameters was assessed by χ2 statistics and
the same applied to the association between TIMP-1
expression and response to chemotherapy.
Overall survival was defined as the elapsed time from
date of diagnosis (date of primary surgery) until death
attributable to any cause. Univariate overall survival anal-
ysis was performed using the Kaplan-Meier estimates and
log-rank statistics for comparison of survival curves.
Statistical analyses were performed with the NCSS soft-
ware (version 2007, Kaysville, Utah, http://
www.ncss.com). A value of p < 0.05 was considered statis-
tically significant.
Results
Patient characteristics and TIMP-1 immunostaining
All patients received first line combination carboplatin
and cyclophosphamide as outlined in the protocol [23].
The majority of patients had serous ovarian cancer (79%).
The patient characteristics are summarized in Table 1
together with the results of the TIMP-1 immunohis-
tochemical staining.
Follow up time since date of surgery was at least 15
years with a median follow-up of 1.9 years, (range 0.24-
18.1 years) from the date of primary surgery until death
or censoring. Survival data were available for all 163
patients. At censoring time (April 2009) 142 patients
were deceased (death of any course).
The two senior pathologist' (MW and RKC) indepen-
dently agreed on the TIMP-1 scoring in 89% of the cases
and the interobserver Kappa value was 0.601.
Positive TIMP-1 tumour cell immunoreactivity (Fig. 2)
was found in 12.3% of the tumours. Staining was mainly
cytoplasmatic although localized membranous staining
was also seen. Only scarce staining was found in the
stromal compartments. Moreover, immunohistochemical
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Figure 1 TMA used for TIMP-1 immunohistochemistry
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Table 1: Patient characteristics.
Characteristics No of patients % TIMP-1 negative
N (%)
TIMP-1 positive
N (%)
P
Age 0.34
<50 47 28.8 44 (93.6) 3 (6.4)
51-65 94 57.7 80 (85.1) 14 (14.9)
> 65 22 13.5 19 (86.4) 3 (12.3)
Median 55.2
Range 29-70
FIGO stage 0.36
I 0 0
II 26 15.9 25 (96.2) 1 (3.8)
III 123 75.5 106 (86.2) 17 (13.8)
IV 14 8.6 12 (85.7) 2 (14.3)
Tumour grade 0.32
1 34 20.9 28 (82.4) 6 (17.6)
2 49 30.1 43 (87.8) 6 (12.2)
3 66 40.5 61 (92.4) 5 (7.6)
Not graded (clear cell or 
metastatic biopsy/cytology only)
14 8.6
Histopathologic cell type 0.00004
Serous 129 79.1 119 (92.2) 10 (7.8)
Endometrioid 11 6.8 9 (81.8) 2 (18.2)
Clear cell 5 3.1 4 (80.0) 1 (20.0)
Mucinous 9 5.5 4 (44.4) 5 (55.6)
Undifferentiated 6 3.7 6 (100) 0 (0.0)
Carcinosarcoma 3 1.8 1 (33.3) 2 (66.7)
Residual postoperative tumour 0.95
≤ 1 cm 60 44.4 53 (88.3) 7 (11.7)
> 1 cm
(Unknown: 28)
75 55.6 66 (88.0) 9 (12.0)
TIMP immunostaining
Negative 143 87.7 NA NA NA
Positive 20 12.3
(<0.1%: 26)
(0.1-10%: 80)
(>10-25%: 30)
(>25-50%:17)
(>50%: 10)
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against trinitrophenyl hapten (TNP) did not show any
positive staining. TIMP-1 immunoreactivity was not cor-
related with age at diagnosis, FIGO stage, grade or resid-
ual tumour size. Histopathologic cell type was correlated
to TIMP-1 immunoreactivity (p = 0.00004, χ2) with low
percentage of TIMP-1 positive cases in serous (7.8%) and
undifferentiated tumours (0%) compared to a higher rate
of TIMP-1 positive tumours in endometrioid (18.2%,
clear cell (20%), mucinous (55.6%) and carcinosarcomas
(66.7%). However, these results should be taken with cau-
tion since the groups with non-serous tumours were
rather small.
The staining of the TMA cores reflected the observa-
tion made in twenty whole sections as all patients that
scored negative by evaluation of whole sections also
scored negative by evaluation of the TMA. The same
applied to tumours with positive TIMP-1 expression. In
detail, five out of the twenty the whole sections scored
positive and the same applied to the five TMA's from the
corresponding tumours. None of the fifteen whole sec-
tions with negative TIMP-1 score scored positive in the
TMA's. Since all cores showed preservation of the origi-
nal score, tumour heterogeneity did not appear to play an
important role.
TIMP-1 and response
For 106 patients with CA-125 data, the baseline serum
CA-125 level (pre-treatment) was elevated to at least
twice the upper normal limit. Furthermore, by measuring
serum CA-125 at each cycle of chemotherapy it was pos-
sible to assess CA-125 response according to GCIG CA-
125 response criteria as proposed by Rustin et al [28,29].
Among patients with TIMP-1 negative tumours 87%
achieved a CA-125 response compared to patients with
TIMP-1 positive tumours where 93% reached a CA-125
response according to GCIG criteria (p = 0.53, Table 2).
Second look surgery was optional in the protocol and 92
out of the 163 patients had second look surgery per-
formed. For patients with TIMP-1 negative tumours 32%
had complete and 52% had partial response by biopsy and
clinical assessment at second surgery compared to 18%
with complete and 55% with partial response in patients
with TIMP-1 positive tumours (p = 0.72, Table 3). The
total response rate at second look surgery (CR+PR) of
84% for patients with TIMP-1 negative tumours was not
significantly different from the 73% total response rate for
patients with TIMP-1 positive tumours (p = 0.36).
Accordingly, TIMP-1 expression status did not seem to
influence the response to carboplatin and cyclophosph-
amide in first line chemotherapy, neither when assessed
by CA-125 nor by second look operation.
Figure 2 TIMP-1 immunohistochemical staining. A. Negative TIMP-1 staining (X200): Serous adenocarcinoma with staining intensity=0 (absent) 
and percentage positive cells =0 (no tumor cells with staining). B. Negative TIMP-1 staining (X200): Serous adenocarcinoma with staining intensi-
ty=1 (weak) and percentage positive cells =2 (between >10% and 25% tumor cells with staining). C. Negative TIMP-1 staining (X200): Serous ade-
nocarcinoma with staining intensity=2 (moderate) and percentage positive cells =1 (between >0% and 10% tumor cells with staining). D. Positive 
TIMP-1 staining (X200): Serous adenocarcinoma with staining intensity=2 (moderate) and percentage positive cells =4 (>50% tumor cells with 
staining). E. Positive TIMP-1 staining (X200): Serous adenocarcinoma with staining intensity=3 (strong) and percentage positive cells =3 (between 
>25% and 50% tumor cells with staining).
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The median survival time for all 163 patients was 23.5
months [18.9-27.9 months] 95% CI, with an overall sur-
vival range of 3 to 220 months. Significant prognostic
markers in univariate survival analysis were age at diag-
nosis (p = 0.004), FIGO stage (p = 0.0001), histological
tumour grade (p = 0.0005), histology (p = 0.0005) and
residual tumour after primary surgery (p = 0.0001). (Data
not shown).
The median survival time for the 143 patients with
TIMP-1 negative tumours was 23.7 months [19.0-29.4]
95% CI, while the median survival for the 20 patients with
TIMP-1 positive tumours was 15.9 months [12.3-27.4]
95% CI. (Fig. 3). Although there seems to be a trend
towards longer survival of TIMP-1 negative patients, the
results did not show a significant difference (p = 0.28,
Kaplan Meier, log-rank test).
Discussion
We demonstrate here that TIMP-1 protein is present in
the tumour tissue in a subgroup of ovarian cancer
patients but its presence is neither correlated with overall
survival nor CA-125 determined response or with objec-
tive response to combination chemotherapy with carbo-
platin and cyclophosphamide.
The monoclonal antibody used for TIMP-1 immunos-
taining has previously [27] been selected and validated
among a panel of anti-TIMP-1 antibodies for its sensitiv-
ity and specificity and furthermore, in the present study
we found 100% agreement between the scoring results
from the TMA and from the whole slides. Moreover,
immunohistochemical staining with an IgG1 monoclonal
antibody raised against trinitrophenyl hapten (TNP)
which is a non-sense construct did not show any positive
staining. Therefore, we believe that the TIMP-1 immu-
nostaining of the paraffin-embedded slides are correct
and robust. We used an arbitrary score of 25% positivity
to divide the patients into subgroups as we preferred a
simple division into positive and negative. We could also
have used a more mathematical approach and multiplied
TIMP-1 staining percentage with the staining intensity to
achieve an H-score. We actually tried this further subdi-
vision and calculated an H-score but this did not change
the final conclusions that TIMP-1 immunoreactivity was
not associated with patient outcome in this cohort of
ovarian cancer patients. Furthermore, calculating an H-
score gave us a score between 0-9 and left us with a rather
low number of patients in each group, some of them even
very small. This could easily lead to results without scien-
tific value.
In contrast to breast cancer where up to 75% of the
tumours appear to be TIMP-1 positive [9] we only scored
12.3% of the cells as TIMP-1 positive. Apart from differ-
ences in the assessment of TIMP-1 immunoreactivity this
dissimilarity can also be explained by a genuine difference
between breast cancer and ovarian cancer. This is under-
lined by the findings in the present study where TIMP-1
immunoreactivity was significantly lower in patients with
serous histology, which constitutes the major part of epi-
thelial ovarian cancers. In breast cancer the most fre-
quent histology is ductal carcinoma. From our data it
appears that TIMP-1 immunoreactivity was significantly
different for the different histopathologic cell types. The
present study showed no worse prognosis in patients with
high TIMP-1 expression although no firm conclusion can
be made for the group of patients with non-serous cancer
since this group were too small for performing a separate
survival analysis although it may be interesting to investi-
gate in a larger material whether the higher level of
TIMP-1 expression may effect survival in ovarian cancer
patients with non-serous tumors.
The previously reported association between high
TIMP-1 levels in ovarian cancer patients and shorter sur-
vival [18,19] was not observed in our group of patients.
However, these two prior studies investigated TIMP-1
levels in serum [18] and plasma [19] in a smaller popula-
tion including only 59 and 40 ovarian cancer patients,
respectively.
In the present study, TIMP-1 expression was detected
by means of immunohistochemical staining in TMA
made from paraffin blocks of primary ovarian cancer
specimens which may be one explanation of the differ-
ences compared to studies evaluating levels of TIMP-1 in
blood samples. This is supported by studies in primary
Table 2: Relationship between TIMP-1 tumour cell immunoreactivity and treatment efficacy.
TIMP-1 expression
Negative (n = 92) Positive (n = 14) p
CA-125 GCIG Response 0.53
Response (n = 93) 80 (87%) 13 (93%)
Non-response (n = 13) 12 (13%) 1 (7%)
Correlation between TIMP-1 expression and CA125 response (N = 106)
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between tumour tissue TIMP-1 levels and blood levels of
TIMP-1 have been published [30,31].
Interestingly, several studies have shown a significantly
lower level of TIMP-1 immunohistochemical protein
staining in invasive ovarian cancer samples compared to
borderline and benign ovarian tumours [32,33], while one
study [20] found a higher concentration of TIMP-1 (by
ELISA technique in tissue homogenates) in both malig-
nant, borderline and benign tumours compared to the
concentration in normal ovaries which underlines the
generally increased amount of TIMP-1 protein in ovarian
tumours regardless of tumour invasiveness. This is sup-
ported by our study in which we did not find statistically
higher TIMP-1 immunoreactivity in high grade ovarian
cancer patients or in patients with an advanced FIGO
stage. In contrast to the studies by Brun et al [33] and by
Sakata et al [32], which point to a higher TIMP-1 protein
expression in benign and borderline tumours compared
to invasive tumours, diagnostic reports have almost all
shown higher levels of TIMP-1 in plasma or serum from
invasive malignant tumours compared to benign or bor-
derline tumours [17-19]. This discrepancy could be
explained by the production of TIMP-1 from other
sources than cancer cells, e.g. by stroma cells. Extensive
evidence in the literature supports that cancer progres-
sion co-depends on the stromal compartment to create a
more tumour-promoting microenvironment. In our
material the TIMP-1 staining in stroma was rather scarce
and the TIMP-1 immunoreactivity in the stroma did not
seem to be very pronounced. The study by Brun et al [33]
evaluated the TIMP-1 immunoreactivity in stroma and in
tumour cells in serous and mucinous ovarian tumours
and found a tenfold higher TIMP-1 signal in epithelial
tumour cells compared to stroma cells. In a second study
by Huang et al [21] of epithelial ovarian tumours also
seemed to show lower expression of TIMP-1 in stroma
cells than in tumour cells although no direct comparison
was made in this study. Consequently, high amounts of
TIMP-1 in adjacent tissue do not seem to be an obvious
explanation.
By inhibiting MMP activity TIMP-1 is a potential inhib-
itor of tumour growth and metastasis. It therefore seems
paradoxical that elevated expression of TIMP-1 has been
associated with more aggressive cancers. However,
TIMP-1 may have other functions that are independent
of its MMP-inhibiting effect. For example, an antiapop-
totic effect and a growth-promoting activity of TIMP-1
on a variety of cell types has been described [2-6] which
may partially explain its ambiguous role in tumour pro-
gression. However, TIMP-1 in ovarian tumours may not
favor tumour growth or metastases explaining the
Table 3: Relationship between TIMP-1 tumour cell immunoreactivity and treatment efficacy.
TIMP-1 expression
Negative (n = 81) Positive (n = 11) p
Second look Response 0.72
CR
(n = 28)
26 (32%) 2 (18%)
PR
(n = 48)
42 (52%) 6 (55%)
SD
(n = 11)
9 (11%) 2 (18%)
PD
(n = 5)
4 (5%) 1 (9%)
Correlation between TIMP-1 expression and response at second look surgery (N = 92)
Figure 3 Kaplan Meier Overall Survival (OS) curves and TIMP-1. 
Median OS for patients with TIMP-1 negative tumours (N = 139): 23.7 
months [19.0-29.4] 95% CI. Median OS for patients with TIMP-1 positive 
tumours (N = 21): 15.9 months [12.3-27.4] 95% CI.
Steffensen et al. BMC Cancer 2010, 10:185
http://www.biomedcentral.com/1471-2407/10/185
Page 9 of 10observed lack of association between TIMP-1 and patient
prognosis in our study. Nevertheless, it should be empha-
sized that the lack of correlation between TIMP-1 immu-
noreactivity and patient outcome may be also explained
by other factors such as subsequent additional, different
lines of chemotherapy.
Compelling data has been published arguing that
TIMP-1 may be associated with response to only certain
classes of chemotherapy. In two breast cancer studies lack
of tumour cell TIMP-1 immunoreactivity [9] or low levels
of TIMP-1 in tumour homogenates [34] predicted sensi-
tivity to antracycline-containing therapy but not to cyclo-
phosphamide, methotrexate and 5-fluorouracil in
adjuvant treatment. In another study in which colorectal
cancer patients were treated with irinotecan, 5-fluoroura-
cil and folinic acid [10], low plasma TIMP-1 was signifi-
cantly and independently associated with higher
probability of obtaining an objective response to chemo-
therapy (OR = 3.5, p = 0.007). Since antracyclines are
topoisomerase-2 inhibitors and irinotecan is a topoi-
somerase-1 inhibitor TIMP-1 may particularly interact
with topoisomerase inhibitors. In the present study
patients were treated with carboplatin and cyclophosph-
amide. Therefore, the lack of an association between
TIMP-1 immunoreactivity and response to therapy or
survival may be explained by the fact that these cytostatic
drugs do not belong to the class of topoisomerase inhibi-
tors, although the evidence for this hypothesis is still lim-
ited. The intriguing question raised by these studies of
whether TIMP-1 is associated with resistance to topoi-
somerase inhibitors requires further validation. Ovarian
cancer patients are often treated with antracyclines in the
case of platinum resistant relapse and it may therefore be
of interest to investigate whether positive TIMP-1 immu-
noreactivity would be associated with resistance to antra-
cycline treatment in platinum resistant ovarian cancer
patients.
Conclusions
TIMP-1 protein is present in the tumour tissue in a sub-
group of patients with primary epithelial ovarian cancer.
TIMP-1 immunoreactivity was in the present study nei-
ther correlated with overall survival nor CA-125 deter-
mined response or with objective response to
combination chemotherapy with carboplatin and cyclo-
phosphamide.
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